首页> Annals of hematology> Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).

Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).

导出 OA

翻译打印收藏纠错

第一作者： Anne,Quinquenel

第一单位： Hôpital Robert Debré, Reims, France. aquinquenel@chu-reims.fr.

作者： Anne,Quinquenel ^[1] ; Stéphane,Leprêtre ^[2] ; Marie Sarah,Dilhuydy ^[3] ; Lucile,Bussot ^[4] ; Zora,Marjanovic ^[5] ; Omar,Benbrahim ^[6] ; Romain,Guièze ^[7] ; Alberto,Santagostino ^[8] ; Caroline,Dartigeas ^[9] ; Pierre,Feugier ^[10] ; Damien,Roos-Weil ^[11] ; Ghandi,Damaj ^[12] ; Kamel,Laribi ^[13] ; Loic,Ysebaert ^[14] ; Vincent,Levy ^[15]

作者单位： Hôpital Robert Debré, Reims, France. aquinquenel@chu-reims.fr. ^[1] Centre Henri-Becquerel, Rouen, France. ^[2] Hôpital du Haut-Lévêque, Bordeaux, France. ^[3] CHU Grenoble Alpes, Grenoble, France. ^[4] Hôpital Saint-Antoine, Paris, France. ^[5] CHR Orléans, Orléans, France. ^[6] CHU Estaing, Clermont-Ferrand, France. ^[7] Hôpital Simone Veil, Troyes, France. ^[8] CHU Tours, Tours,, France. ^[9] CHU Régional de Nancy, Vandoeuvre lès Nancy, France. ^[10] CHU Pitié Salpêtrière, Paris, France. ^[11] CHU Caen, Caen, France. ^[12] CH le Mans, Le Mans, France. ^[13] IUCT-Oncopôle , Toulouse, France. ^[14] Hôpital Avicenne, Bobigny, France. ^[15]

DOI 10.1007/s00277-025-06632-3

PMID 41081869

发布时间 2025-11-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交